Company Filing History:
1 out of 989 
1 out of 21 
1 out of 1 Years Active: 2024
Title: Masaki Yamagami: Innovator in Cancer Therapeutics
Introduction
Masaki Yamagami, based in Osaka, Japan, is a noteworthy inventor whose contributions are making significant strides in cancer treatment. With a focus on innovative therapeutics, Yamagami's work has the potential to advance medical practices and improve patient outcomes, particularly for those diagnosed with small cell lung cancer.
Latest Patents
Yamagami holds a patent for a small cell lung cancer therapeutic agent, specifically an oligonucleotide that targets the human nSR100 gene. This invention has demonstrated promising activity in inhibiting the expression of the nSR100 gene, which is crucial for the treatment of various cancers, including prostate and breast cancer. The oligonucleotide, with a length of 12 to 20 mer, is designed to bind to a specific target region, thus providing a novel approach to cancer therapy.
Career Highlights
Throughout his career, Masaki Yamagami has been associated with prestigious institutions such as Osaka University and the National Institutes of Biomedical Innovation, Health and Nutrition. These affiliations have allowed him to collaborate with other prominent figures in the field, contributing to his rich body of work and innovations in biomedicine.
Collaborations
Yamagami has worked alongside reputable collaborators including Masahito Shimojo and Satoshi Obika. These partnerships have enabled the exchange of ideas and knowledge, further enhancing the development of effective cancer therapies. Collaboration within such esteemed networks underscores the importance of teamwork in advancing medical innovation.
Conclusion
Masaki Yamagami's dedication to advancing cancer therapeutics exemplifies the critical role of inventors in modern medicine. With his patent on a therapeutic agent targeting nSR100, he is contributing significantly to the fight against cancer, potentially offering new hope to patients worldwide. As innovations in this field continue to evolve, Yamagami's work remains a vital part of the ongoing journey toward effective cancer treatment.